Accelerating Cancer Treatment Insights Through Innovative Technology
Every moment can be critical in cancer care, and First Ascent Biomedical is committed to helping patients swiftly. By utilizing a patient's live cancer cells for testing outside the body, the company provides insights into how those cells respond to FDA-approved medications before any formal treatment begins. This innovative approach allows personalized treatment options to be available in roughly ten days, ensuring timely interventions that could potentially save lives.
Revolutionizing Traditional Cancer Protocols
Traditionally, the standard of care in cancer treatment was predominantly based on broad clinical research conducted with large populations, established back in the 1990s. However, individual patient biology varies significantly, and a one-size-fits-all model may not be effective for everyone. Around the turn of the century, the advent of DNA and RNA sequencing, biomarker discovery, and targeted therapies began to alter the landscape of cancer treatment. Yet, the time these methods often take can be detrimental as the disease progresses rapidly.
Pioneering Functional Precision Medicine
First Ascent Biomedical introduces a transformative approach with its Functional Precision Medicine (FPM) platform. This cutting-edge technology merges functional drug analysis, genomic sequencing, and artificial intelligence (AI) to yield personalized insights. By focusing on patients' live cancer cell responses before any treatment, the system can reveal how each unique tumor behaves, aligning treatment plans to individual needs swiftly.
Patients undergo testing to determine how their tumors react to over 150 FDA-approved drugs and various combinations. Due to this integrated approach, oncologists can now make informed choices based on real-world biological data, enhancing the potential for successful outcomes. As Jim Foote, co-founder of First Ascent Biomedical states, "Cancer doesn't wait for lab results, so we built a system that doesn’t either."
Breaking Down Misconceptions About Oncology
A significant misconception in cancer treatment is that functional precision medicine might overshadow genomics. In truth, it complements it; genomics provides vital data akin to sheet music while functional precision medicine acts like the orchestra, performing a symphony that illustrates how tumors respond to treatments. This combined approach fosters a deeper understanding for clinicians, as live-cell results can be presented in standard tumor board meetings, enhancing decision-making and treatment prioritization.
Improving Speed, Scalability, and Validation in Cancer Care
In recent years, FPM has evolved, moving past the perception of being slow or overly specialized. Current technological advancements including automation and robotics allow First Ascent's platform to deliver clinical results in an average of just ten days. This rapid turnaround can transform treatment strategies, leading to:
- Validated response improvement: 83% of patients exhibited improved responses to treatments identified through FPM.
- Durability of response: Patients remained cancer-free 8.5 times longer compared to their previous therapies.
- Clinical readiness: Tests are conducted in CLIA-certified laboratories, ensuring reliability and approval through peer-reviewed publications.
This blend of quick, precise, and validated insights enables oncologists to transition beyond conventional, population-based frameworks, leveraging analytics from First Ascent to enhance treatment efficacy in real time.
Impact of Speed on Patient Outcomes
The implications for patients are profound; refined insights from the platform yield fewer adverse effects from unsuitable drugs, minimizing the time lost in trial-and-error methods while maximizing the time for effective action. For families, these accelerated insights foster hope and invaluable moments together even amid difficult journeys.
Consider the case of Logan, a young boy whose cancer resisted conventional treatments. Although initial genetic testing did not reveal a clear solution, First Ascent's platform uncovered a promising drug combination that effectively addressed his condition. With this knowledge, his medical team swiftly revised his treatment plan, leading to his current cancer-free status.
The Role of AI in Functional Precision Medicine
AI is integrally woven into the FPM approach, making it both effective and scalable. By marrying functional drug response data with genomic sequences, AI can:
- Identify likely responders among patients.
- Anticipate resistance patterns.
- Explore potential drug combinations.
- Highlight biomarkers that take treatment strategies further.
As the volume of data continues to grow, the platform simultaneously enhances its intelligence, empowering healthcare professionals to make smarter, faster decisions across various tumor types.
About First Ascent Biomedical
First Ascent Biomedical is at the forefront of revolutionizing cancer treatment. Through its AI-driven Drug Prediction Platform, the organization seamlessly integrates genomic analysis and drug sensitivity testing, identifying personalized therapies for all solid and liquid tumors. This approach not only accelerates test results to an average of ten days but also improves patient outcomes by steering treatment away from ineffective options.
Frequently Asked Questions
What is Functional Precision Medicine?
Functional Precision Medicine is an innovative approach that tailors cancer treatments based on how live cancer cells respond to medications, ensuring personalized care.
How quickly does First Ascent Biomedical deliver test results?
The platform provides actionable insights within an average of ten days, enabling timely treatment decisions.
Can genomics and functional precision medicine work together?
Yes! Functional precision medicine complements genomic data by providing real-world insights on tumor responses, enhancing treatment strategies for oncologists.
What makes First Ascent Biomedical unique in cancer treatment?
First Ascent Biomedical combines live cell testing, DNA/RNA sequencing, and AI to expedite personalized treatment options, marking a significant advancement in oncology.
How does this technology impact patient outcomes?
By providing faster insights into effective treatments, patients face fewer side effects from unsuitable medications, leading to increased survival rates and improved quality of life.
